Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded up 27.6% on Friday . The stock traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.35 ($0.04). 8,992,934 shares changed hands during trading, a decline of 61% from the average session volume of 23,308,711 shares. The stock had previously closed at GBX 2.63 ($0.03).
ImmuPharma Stock Performance
The company has a 50 day moving average of GBX 1.59 and a two-hundred day moving average of GBX 1.69. The stock has a market capitalization of £13.95 million, a PE ratio of -335.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- What is the Shanghai Stock Exchange Composite Index?
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Stock Sentiment Analysis: How it Works
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
